Clinical trial · Observational
Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE)
Study of Predictive Biomarkers of Response to Carboplatin Etoposide Atezolizumab Combination in Patients With Small Cell Lung Cancer, Exploratory Study by HYPErionTM Tissue Mass Imaging
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this retrospective study is to identify predictive biomarkers of efficacy in tumor samples of small cell lung cancer patients treated with chemotherapy-immunotherapy combination using imaging mass cytometry. The main question it aims to answer is: is there any feature in the tumour microenvironment that can discriminate responders from non responders before treatment? Participants will provide consent for the collection of their clinical data and the study of their tumor samples
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Carcinoma | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Identification of predictive biomarkers of anti-PD-L1 efficacy in the tumor of small cell lung cancer patients
- timeFrame
- 3 year
- description
- Features in the tumour microenvironment that can discriminate patients responding to anti-PD-L1 from non responders
Secondary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- 3 year
- description
- Time between treatment start and date of progression according to investigator, or death from any cause
- measure
- Overall survival
- timeFrame
- 3 year
- description
- Time between treatment start and date of death from any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with extensive or metastatic small cell lung cancer * Patients who started a first line treatment with atezolizumab plus carboplatin and etoposide in routine practice before February 2021 * Patients with available tumor sample before treatment start * No objection from living patients Exclusion Criteria: * Patients who started first line treatment with atezolizumab plus carboplatin and etoposide in routine practice after February 2021 * Patients having received immunotherapy in a clinical trial * Patients with auto-immune disorder * Patients under legal protection (guardianship, curatorship) * Patients refusing to participate to the study
References
Publications (0)
Data not yet available